Literature DB >> 13303167

[The effect of the follicular hormone on uterine carcinoma].

H HUSSLEIN, E SCHULLER.   

Abstract

Entities:  

Keywords:  ESTROGENS/effects; UTERUS/neoplasms

Mesh:

Substances:

Year:  1955        PMID: 13303167     DOI: 10.1007/BF00985844

Source DB:  PubMed          Journal:  Arch Gynakol        ISSN: 0003-9128


× No keyword cloud information.
  23 in total

1.  [Relation between glandular hyperplasia and cancer of the uterus].

Authors:  R KELLER
Journal:  Bull Fed Soc Gynecol Obstet Lang Fr       Date:  1952

2.  [Cervical carcinoma occurring after 17 years of estrogen therapy].

Authors:  H RIEHM; P STOLL
Journal:  Geburtshilfe Frauenheilkd       Date:  1952-11       Impact factor: 2.915

3.  Uterine adenocarcinoma in a patient receiving estrogens.

Authors:  E R NOVAK
Journal:  Am J Obstet Gynecol       Date:  1951-09       Impact factor: 8.661

4.  Cancer of endometrium and prolonged estrogen therapy.

Authors:  M FREMONT-SMITH; J V MEIGS
Journal:  J Am Med Assoc       Date:  1946-07-06

5.  Malignant lesions of the uterus associated with estrogen-producing ovarian tumors; report of two cases.

Authors:  E MUSSEY; M B DOCKERTY; J C MASSON
Journal:  Proc Staff Meet Mayo Clin       Date:  1948-02-04

6.  [Role of glandular-cystic hyperplasia in etiology of cervical adenocarcinoma].

Authors:  E RIMBACH
Journal:  Zentralbl Gynakol       Date:  1953

7.  [The follicular hormone as etiological factor in adenocarcinoma of the uterine body].

Authors:  H G MULLER
Journal:  Z Geburtshilfe Gynakol       Date:  1951

8.  Endometrial. carcinoma associated with feminizing ovarian tumors.

Authors:  J M INGRAM; E NOVAK
Journal:  Am J Obstet Gynecol       Date:  1951-04       Impact factor: 8.661

9.  [Significance of the estrogens in the pathogenesis of uterine cancer].

Authors:  A TERP
Journal:  Ugeskr Laeger       Date:  1950-09-14

10.  Precursors of corpus carcinoma estrogens and adenomatous hyperplasia.

Authors:  S B GUSBERG
Journal:  Am J Obstet Gynecol       Date:  1947-12       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.